TORC resTORbio Inc.

-0.04  -0%
Previous Close 8.12
Open 8.11
Price To Book 2.06
Market Cap 288805686
Shares 35,743,278
Volume 68,561
Short Ratio
Av. Daily Volume 207,717

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 top-line data due mid-2020.
RTB101 and Everolimus
Respiratory Tract Infections
Phase 2 data due 2020.
Parkinson's disease

Latest News

  1. resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with Asthma
  2. resTORbio Reports First Quarter 2019 Financial Results and Corporate Update
  3. resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer
  4. resTORbio to Present RTB101 Phase 2b Clinical Trial Data at American Thoracic Society 2019 International Conference
  5. resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness
  6. resTORbio to Participate at Upcoming Investor Conferences in May
  7. featured expert Kevin Matras highlights: Walker & Dunlop, Herc, ICICI Bank, HDFC Bank and resTORbio
  8. Buy These 5 Stocks as New Analysts Initiate Coverage
  9. resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s Disease
  10. resTORbio, Inc. Announces Closing Public Offering of Common Stock
  11. resTORbio, Inc. Announces Pricing of Public Offering of Common Stock
  12. resTORbio, Inc. Announces Proposed Public Offering of Common Stock
  13. resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results
  14. resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101
  15. resTORbio to Present at 8th Annual SVB Leerink Global Healthcare Conference
  16. resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal Chemistry
  17. resTORbio to Host Key Opinion Leader Symposium on TORC1 Inhibition and Neurodegenerative Disease
  18. resTORbio Appoints William Marshall, M.D., as Vice President of Medical Sciences
  19. resTORbio Reports Third Quarter 2018 Financial Results
  20. resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific Meeting